PASSPORT

In 2006, over 45.000 European citizens died of cirrhosis of the liver and 44,000 additional citizens of liver cancer, knowing that the same year 48,700 new liver cancer cases were declared. Surgical procedures remain the options that offer the foremost success rate against such pathologies. Regretfully, surgery is not so frequent due to several limitations.

Indeed, eligibility for liver surgery is based on the minimum safety liver volume remaining after resection (standardized FLR), but this minimum value varies over time and from one patient to another according to biological and mechanical properties of the liver. Since 1996, a large set of preoperative planning software has been developed, but all of them provide only the volume of the liver before and after resection. However interesting, this limited information is not sufficient to improve the rate of surgical eligibility.

PASSPORT for Liver Surgery (PAtient specific simulation and preoperative realistic training for liver surgery) project aims at overcoming these limitations by offering a patient-specific modelling that combines anatomical, mechanical, appearance and biological preoperative modelled information in a unified model of the patient. This first complete "Virtual liver" will be developed in an Open Source Framework allowing vertical integration of biomedical data, from macroscopic to microscopic patient information.

From these models, a dynamic liver modelling will provide the patient-specific minimum safety standardized FLR in an educative and preoperative planning simulator allowing to predict the feasibility of the gesture and surgeons' ability to realise it. Thus, any patient will be able to know the risk level of a proposed therapy.

The propsed project expects to increase the rate of surgical treatment so as to save patients with a liver pathology. To reach these purposes, PASSPORT is composed of a high level partnership between internationally renowned surgical teams, leading European research teams in surgical simulation and an international leading company in surgical instrumentation.

For further information, please visit:
http://www.passport-liver.eu

Project co-ordinator:
Institut de Recherche contre les Cancers de l'Appareil Digestif (France)

Partners:

  • Universität Leipzig (Germany)
  • Technischen Universität München (Germany)
  • University College London (United Kingdom)
  • Imperial College of Science, Technology and Medicine (United Kingdom)
  • Karl Storz GmbH & Co. KG (Germany)
  • Université Louis-Pasteur (France)
  • Institut National de Recherche en Informatique et en Automatique (France)
  • Eidgenössische Technische Hochschule Zürich (Switzerland)
  • Université catholique de Louvain (Belgium)

Timetable: from 06/2008 - to 05/2011

Total cost: € 5.460.000

EC funding: € 3.640.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)

Most Popular Now

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

Overcoming the AI Applicability Crisis a…

Opinion Article by Harry Lykostratis, Chief Executive, Open Medical. The government’s 10 Year Health Plan makes a lot of the potential of AI-software to support clinical decision making, improve productivity, and...

Smart Device Uses AI and Bioelectronics …

As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called "a-Heal," designed by engineers at the University...

Dartford and Gravesham Implements Clinis…

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering using Clinisys ICE. The trust deployed the order communications...

AI Body Composition Measurements can Pre…

Adiposity - or the accumulation of excess fat in the body - is a known driver of cardiometabolic diseases such as heart disease, stroke, type 2 diabetes, and kidney disease...